Cancer Anorexia-Cachexia Syndrome (CACS) Market Report 2026

Cancer Anorexia-Cachexia Syndrome (CACS) Market Overview

• Cancer Anorexia-Cachexia Syndrome (CACS) market size has reached to $3.88 billion in 2025 • Expected to grow to $6.37 billion in 2030 at a compound annual growth rate (CAGR) of 10.4% • Growth Driver: Impact Of Rising Cancer Prevalence On The Market • Market Trend: Monoclonal Antibody Therapies And Pfizer's Promising Phase II Trial Results • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cancer Anorexia-Cachexia Syndrome (CACS) Market?

Cancer anorexia-cachexia syndrome (CACS) is a multifactorial condition commonly seen in cancer patients, marked by severe metabolic disturbances. It involves a combination of inflammatory responses, hormonal changes, and altered nutrient utilization, often leading to poor prognosis and treatment resistance. The indication main types of cancer anorexia-cachexia syndrome (CACS) are weight loss prevention, appetite loss, muscle wasting, inflammation, and others. Weight loss prevention in Cancer Anorexia-Cachexia Syndrome (CACS) involves strategies to maintain body weight and muscle mass, aiming to improve nutritional intake and counteract metabolic imbalances caused by cancer. These are addressed through various therapeutics, including corticosteroids, combination therapies, and others. The treatment mechanisms involve appetite stimulants, anti-inflammatory agents, hormone therapies, cannabinoids, and others. It is administered through different routes, such as oral, intravenous, subcutaneous, transdermal, and others. It is used in various applications like hospitals, clinics, and home care.

What Is The Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth Forecast?

The cancer anorexia-cachexia syndrome (cacs) market size is expected to see rapid growth in the next few years. It will grow to $6.37 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing investments in cachexia drug development, growing focus on personalized oncology supportive care, rising clinical trial activity for novel agents, expansion of home-based cancer care, increasing integration of cachexia management in oncology protocols. Major trends in the forecast period include increasing development of targeted cachexia therapies, rising focus on anti-inflammatory treatment pathways, growing adoption of combination therapeutic approaches, expansion of nutritional and metabolic support solutions, enhanced emphasis on early cachexia intervention.

Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Segmentation

1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications 2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics 3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions 4) By Route of Administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration 5) By Application: Hospitals, Clinics, Home Care Subsegments: 1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators 2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists 3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs) 4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors 5) By Other Indications: Combination Therapies, Supportive Care Interventions

What Are The Drivers Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

Growing prevalence of cancer expected to propel the growth of the cancer anorexia-cachexia syndrome market going forward. Cancer is a broad term for a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Cancer rates are rising globally due to factors such as an aging population, lifestyle changes, environmental exposures, improved detection methods, and increased awareness, along with genetic predispositions and infections linked to certain cancers. Cancer anorexia-cachexia syndrome (CACS) helps address the growing prevalence of cancer by focusing on managing the severe weight loss and malnutrition often seen in cancer patients, improving their overall quality of life and treatment outcomes. For instance, in August 2024, according to a report published by the Macmillan Cancer Support, a UK-based charitable organization, over 3 million people in the UK are living with cancer, and this number is expected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the growing prevalence of cancer is driving the growth of the cancer anorexia-cachexia syndrome market. Increasing healthcare expenditure is expected to propel the growth of the cancer anorexia-cachexia syndrome market going forward. Healthcare expenditure refers to the total amount of financial resources spent on healthcare services, including public and private sector spending. Increasing healthcare expenditure is driven by factors such as the aging population, rising prevalence of chronic diseases, advancements in medical technology, and higher demand for quality healthcare services. Cancer Anorexia-Cachexia Syndrome (CACS) drives increasing healthcare expenditure by necessitating specialized treatments, nutritional support, and palliative care for patients, contributing to higher costs for managing cancer-related complications. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the cancer anorexia-cachexia syndrome market.

Key Players In The Global Cancer Anorexia-Cachexia Syndrome (CACS) Market

Major companies operating in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Trends and Insights

Major companies operating in the cancer anorexia-cachexia syndrome market are focusing on developing innovative solutions, such as monoclonal antibody therapies, to enhance treatment efficacy, improve patient outcomes, and address unmet clinical needs. Monoclonal antibody therapies are treatments that use laboratory-produced antibodies designed to target specific antigens on cancer cells, helping the immune system recognize and attack them more effectively. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, announced positive results from a Phase II clinical trial of ponsegromab, a monoclonal antibody targeting Growth/Differentiation Factor 15 (GDF-15). The positive data from the study offers hope for a new treatment avenue for patients who suffer from this debilitating condition, for which few effective therapies currently exist. The Phase 2 trial results suggest significant progress in addressing the underlying inflammatory processes contributing to muscle loss and weight decline in cancer patients. This treatment approach aims not only to improve physical function but also to enhance the overall quality of life for cancer patients, marking a pivotal step in oncology care.

Regional Outlook

North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cancer Anorexia-Cachexia Syndrome (CACS) Market?

The cancer anorexia-cachexia syndrome (CACS) market consists of revenues earned by entities by providing services such as nutritional support, pharmacological treatments, palliative care, clinical trials, and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cancer Anorexia-Cachexia Syndrome (CACS) Market Report 2026?

The cancer anorexia-cachexia syndrome (cacs) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cancer anorexia-cachexia syndrome (cacs) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.